Epstein-Barr Virus and Associated Diseases: Proceedings of the First International Symposium on Epstein-Barr Virus-Associated Malignant Diseases (Loutraki, Greece—September 24–28, 1984)

694 Pages·1985·24.119 MB·English

by  David T. Purtilo M.D. (auth.), P. H. Levine, D. V. Ablashi, G. R. Pearson, S. D. Kottaridis (eds.)

EPSTEIN-BARR VIRUS
AND ASSOCIATED DISEASES
DEVELOPMENTS IN MEDICAL VIROLOGY
Yechiel Becker, Series Editor
Julia Hadar, Managing Editor
Levine, et al (eds.), Epstein-Barr Virus and Associated Diseases (1985)
EPSTEIN-BARR VIRUS AND
ASSOCIATED DISEASES
Proceedings of the First International Symposium on
Epstein-Barr Virus-Associated Malignant Diseases
(Loutraki, Greece-September 24-28, 1984)
edited by
P.H. Levine
D. V. Ablashi
G.R. Pearson
S.D. Kottaridis
.,
~
Martinus Nijhoff Publishing
a member of the Kluwer Academic Publishers Group
Boston/Dordrecht/Lancaster
Distributors for North America:
Kluwer Academic Publishers
190 Old Derby Street
Hingham, MA 02043, USA
Distributors for the UK and Ireland:
KIuwer Academic Publishers
MTP Press Limited
Falcon House, Queen Square
Lancaster LAI IRN, UK
Distributors for all other countries:
KIuwer Academic Publishers Group
Distribution Centre
P.O. Box 322
3300 AH Dordrecht, THE NETHERLANDS
The figure on the cover is from Proc Natl Acad
Sci USA, 81:4652, 1984, and is used with permission. It also
appears on page 447 of this book.
Library of Congress Cataloging in Publication Data
International Symposium on Epstein-Barr Virus
Associated Malignant Diseases (1 st : 1984 :
Loutraki, Greece)
Epstein-Barr virus and associated diseases.
(Developments in medical virology)
Includes bibliographies.
I. Epstein-Barr virus-Congresses. 2. Nasopharynx
Cancer-Congresses. 3. Oncologic viruses-Congresses.
4. Virus diseases-Congresses. I. Levine, P.H.
(Paul H.) II. Title. III. Series. [DNLM: 1. Epstein
Barr Virus-immunology-congresses. 2. Epstein-Barr
Virus-pathogenicity-congresses. 3. Immunologic
Deficiency Syndromes-congresses. 4. Medical Oncology
congresses. 5. Nasopharyngeal Neoplasms-congresses.
6. Tumor Virus Infections-congresses.
QW 165.5.H3 1616 1984e]
QR400.2.E68157 1984 576' .6484 85-15484
ISBN-13 :978-1-4612-9641-6 e-ISBN-13 :978-1-4613-2625-0
DOl: I 0.1 007/978-1-4613-2625-0
Copyright © 1985 by Martinus Nijhoff Publishing, Boston
Softcover reprint of the hardcover I st edition 1985
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or
transmitted in any form or by any means, mechanical, photocopying, recording, or otherwise, without
written permission of the publisher, Martinus Nijhoff Publishing, 190 Old Derby Street, Hingham,
Massachusetts 02043.
CONTENTS
SERIES PREFACE xi
PREFACE Xlll
ACKNOWLEDGMENTS xv
IMMUNODEFICIENCY DISEASES
1. Association of Epstein-Barr Virus and Lymphoproliferative 3
Diseases in Immune Deficient Persons D. T. PurtUo
2. Relapsing, Recurrent and Chronic Infectious Mononucleosis 18
in the Normal Host S.E. Straus
3. Immune Assessment of Patients with Chronic Active EBV 34
Infection (CAEBV) J.F. Jones, S.B. Straus, G. Tosato,
R.A. Kibler, M. Hicks, D. Lucas, 0. Preble, T. Lawley,
G. Armstrong, G. Pearson and R.M. Blaese
4. Reversal of Common Variable Hypogammaglobulinemia 43
Associated Suppressor Cell Activity by Specific
Carbohydrates G. Tosato, S.B. Pike and R.M. Blaese
5. Unusual Primary Tumors of Brain and Lungs Associated 53
with Epstein-Barr Virus (EBV) J. Joncas, F. Ghibu,
N. Lapointe, L. Begin, J. Michaud, P. Simard, P. Benoit,
G. Rivard, J. Demers and R. Raymond
6. Lytic, Non-Transforming Epstein-Barr Virus (EBV) from 63
Two Patients with Chronic Active EBV Infection C. Alfieri,
F. Ghibu and J. Joncas
7. Brief Communication: The Significance of Antibodies 73
Against the Epstein-Barr Virus-Specific Membrane Antigen
gp250 in Acute and Latent EBV Infections W. JUg and
H. Wolfe
EBV-ASSOCIATED MALIGNANCIES
8. The Epidemiology of Epstein-Barr Virus-Associated 81
Malignancies P.H. Levine
9. Genetic Aspects of EBV-Associated Malignancies M. Simons 90
10. Pathology of Epstein-Barr Virus (EBV)-Associated Disease 106
(the Lymphatic System) G.R.F. Krueger
11. The "Family Study" Approach to Investigating the Role of 131
Genetic Factors in Nasopharyngeal Carcinoma S.J. Bale,
A.B. Bale and P.H. Levine
v
vi
12. An EBV-Associated Salivary Gland Cancer A.P. Lanier, 145
S. Krishnamurthy, S.E. Clift, K. T. Kline, G. W. Bornkamm,
W. Henle, A. Gown and D. Thorning
13. Nasopharyngeal Carcinoma: Early Detection and IgA 151
Related pre-NPC Condition. Achievements and Prospectives
Y. Zeng and G. de The
14. Evaluation of Epstein-Barr Virus Serologic Analysis in North 164
American Patients with Nasopharyngeal Carcinoma and in
Comparison Groups H.B. Neel, III, G.R. Pearson and
W.F. Taylor
15. Use of Epstein-Barr Virus Serology in the Diagnosis of 180
Nasopharyngeal Carcinoma in Malaysia M. Yadav, N.
Malliha, A. W. Norhanom and U. Prasad
16. An Analysis of the Relationship Between Clinical Pathology 193
and Serological Level of EB Virus VCA-IgA Antibody in
Nasopharyngeal Carcinoma P.S. Huang, Y.D. Chen and
Y. Y. Shen
17. Brief Communication: Fossa of Rosenmuller: The Site for 200
Initial Development of Carcinoma of the Nasopharynx
U. Prasad, J. Singh and R. Patmanathan
18. Brief Communication: Carcino-Embryonic Antigen (CEA) in 207
Nasopharyngeal Carcinoma and Chronic Nasopharyngitis
Y. Y. Shen and P. S. Huang
19. Brief Communication: HLA-Antigens in NPC Patients from 211
a Low-Risk Area (Cologne, FRG) G. Bertram, J. Kruger
and K. Sesterhenn
MOLECULAR BIOLOGY OF EBV
20. Persistence and Expression of the Epstein-Barr Virus 221
Genome in Latent Infection and Growth Transformation of
Lymphocytes E. KiefJ, K. Hennessy, T. Dambaugh,
T. Matsuo, S. Fennewald, M. Heller, L. Petti and
M. Hummel
21. An Epstein-Barr Virus-Determined Nuclear Antigen Encoded 248
by a Region within the EcoRI A Fragment of the Viral
Genome L. Rymo and G. Klein
22. An EBV RNA with a Repetitive Spliced Structure 256
M. Bodescot, B. Chambraud and M. Perricaudet
23. Characterization of an EBV-Associated Protein Kinase 267
E. Fowler
24. Characterization of the Genes within the BamHI Fragment 278
of Epstein-Barr Virus DNA that may Determine the Fate of
Viral Infection J. Sample, A. Tanaka, G. Lancz and
M. Nonoyama
vii
25. Effects of Tunicamycin on Binding of Epstein-Barr Virus 289
N. Ba/achandran and L.M. Hutt-Fletcher
26. Brief Communication: Structure and Expression of the 299
Epstein-Barr Virus Genome P.J. Farrell, J. Dyson,
P. Tuffnell, M. Biggin, T. Gibson, A. Bankier, G. Hudson,
G. Hatfull, S. Satchwell and B. Barrell
27. Brief Communication: Antibody Response to Epstein-Barr 307
Virus-Specific DNase in Thirteen Patients with Naso
pharyngeal Carcinoma J. Y. Chen, R.P. Beas/ey, C.S. Chien
and C. S. Yang
28. Brief Communication: Recent Developments in Nucleic Acid 311
Hybridization H. Wolf, S. Gu, M. Haus and U. Leser
MECHANISMS OF EBV TRANSFORMATION
29. The Host-Cell Range of the Epstein-Barr Virus R. G/aser 319
30. Epstein-Barr Virus (EBV) Growth Transformation is 334
Associated with an Alteration in C-MYC Chromatin
Structure W.H. Schubach, B.H. Steiner and M. Birkenbach
31. Study of Nucleosomal Organization of Chromatin in EBV 345
Producer and Non-Producer Cells V. Zongza and
S.D. Kottaridis
32. Novel Biological Functions Associated with Epstein-Barr 355
Virus DNA B.E. Griffin, D. King and L. Karran
33. EBV DNA Content and Expression in Nasopharyngeal 362
Carcinoma N. Raab-Traub, D. Huang, C. S. Yang and
G. Pearson
34. Transformation of Human Lymphocytes by Coinfection with 373
EBV DNA and Transformation-Defective Virions
D.J. Vo/sky, B. Vo/sky, M. Hedeskog, F. Sinangil and
T.G. Gross
35. Epstein-Barr Virus-Activating Substance(s) from Soil Y. Ito, 383
H. Tokuda, H. Ohigashi, K. Koshimizu and Y. Zeng
36. Hydrocortisone Enhancement of both EBV Replication and 392
Transformation of Human Cord Lymphocytes D. V. Ab/ashi,
J. Whitman, J. Dah/berg, G. Armstrong and J. Rhim
37. Brief Communication: Detection of EBNA and Rescue of 402
Transforming EBV in Megakaryocyte Cells Established in
Culture D. Morgan and D. V. Ab/ashi
EBV PROTEINS
38. Advances in the Identification of EBV-Specific Proteins: 411
An Overview G.R. Pearson
39. Bacterially Synthesized EBNA as a Reagent for Enzyme 426
viii
Linked Immunosorbent Assays G. Milman, D.K. Ades,
M-S Cho, S.c. Hartman, G.S. Hayward, A.L. Scott and
S.D. Hayward
40. Epstein-Barr Virus Nuclear Antigen (EBNA): Antigenicity of 436
the Molecule Encoded by the Bam HI K Fragment of the
EBV Genome M.J. Allday and A.J. MacGillivray
41. The Use of Antibodies Against Synthetic Peptides for 446
Studying the EBV Nuclear Antigen J. Dillner, L. Eliasson,
L. Stern as, B. Kallin, G. Klein and R.A. Lerner
42. Characterization of Two Forms of the 72,000 MW EBNA and 456
a Cross-Reacting Cellular Protein J. Luka, T. Kreojsky,
T. C. Spelsberg, G.R. Pearson, K. Hennessey and E. Kiejj
43. Identification of EBV-Specific Antigens Following Micro- 466
injection of Sub genomic DNA Fragments A. Boyd,
J. Stoerker, J. Holliday and R. Glaser
44. Localization of Epstein-Barr Virus Early Antigen (EA) by 477
Electron Microscopy M. Kishishita, Y. Ito, J. Luka and
G.R. Pearson
45. Selection and Production by Genetechnological Methods of 485
Medically Relevant EBV-related Antigens H. Wolf, M. Motz,
R. Kuhbeck, R. Seibl, G.J. Bayliss, S. Modrow and J. Fan
46. Identification of Multiple Epstein-Barr Virus Nuclear 495
Antigens T.B. Sculley, P.J. Walker, D.J. Moss and
J.H. Pope
47. Brief Communication: Production of Human Monoclonal 504
Antibodies by EBV Immortalization J. Paire and
C. Desgranges
IMMUNOLOGY
48. Cellular Immunity in EBV Infections J.H. Pope 511
49. T Cell Responses to Epstein-Barr Virus Infection 525
A.B. Rickinson
50. Epstein-Barr Virus and Immunosuppression J. Menezes and 535
S.K. Sundar
51. In Vitro Immunogenicity of Human Lymphoid Tumour Cell 553
Lines D.J. Moss, J.A. Staples, S.R. Burrows, J. Ryan and
T.B. Sculley
52. Monocyte Contrasuppression of EBV-Immune Regulatory 562
T Cells G. Tosato, S.E. Pike and R.M. Blaese
53. Analysis of Intratumoral Lymphocyte Subsets in Patients 572
with Undifferentiated Nasopharyngeal Carcinoma T. Tursz,
P. Herait, M. Lipinski, G. Ganem, M. C. Dokhelar,
C. Carlu, C. Micheau and G. de The
ix
54. Potential Usefulness of Isoprinosine as an Immunostimulating 580
Agent in EBV-Associated Disorders: In Vitro Studies
S.K. Sundar, G. Barile and J. Menezes
55. Mechanisms of Expression of a Burkitt Lymphoma-Associated 588
Antigen (Globotriaosylceramide) in Burkitt Lymphoma and
Lymphoblastoid Cell Lines J. Wiels, E.H. Holmes,
N. Cochran, S.l. Hakomori and T. Tursz
CONTROL OF EBV-ASSOCIATED MALIGNANT DISEASE
56. Prevention of EB Virus-Associated Malignant Diseases 603
M.A. Epstein
57. A Perspective on Treatment of EBV Infection States 619
J.S. Pagano
58. Clinical and Pathobiological Features of Burkitt's 631
Lymphoma and their Relevance to Treatment I. Magrath
59. Management of Nasopharyngeal Carcinoma A. T. Huang, 644
I.R. Crocker, S.R. Fisher and M.J. Wallman
60. Treatment of Nasopharyngeal Carcinoma with the Antiviral 660
Drug 9-[(2-Hydroxyethoxymethyl)] Guanine: A Case Report
J. W. Sixbey, E. Thompson and E. C. Douglass
61. EBV-specific Transfer Factor in the Treatment of African 666
Burkitt's Lymphoma: A Pilot Study F.K. Nkrumah,
G. Pizza, D. Viza, J. Neequaye, C. DeVinci and P.H. Levine
62. Brief Communication: The Teatment of Nasopharyngeal 673
Carcinoma (NPC) J.H. Ho
SPECIAL LECTURE
63. Epstein-Barr Virus: Past, Present and Future G. Henle and 677
W. Henle
LIST OF PARTICIPANTS 687
PREFACE TO THE SERIES, DEVELOPMENTS IN MEDICAL VIROLOGY
It is my pleasure to introduce the first volume in our new series,
Developments in Medical Virology. This series is planned to add another
dimension to our understanding of the processes involving viruses as
pathogens of cells and organisms. Our series Developments in Molecular
Virology is devoted to the basic molecular aspects of virus replication,
while Developments in Veterinary Virology deals with viral disease processes
in domestic animals.
It is hoped that Developments in Medical Virology will provide advanced
information on the understanding of virus diseases of man. The current
volume deals in depth with various aspects of Epstein-Barr virus. Forth
coming volumes will be devoted to viruses affecting various organs and will
also focus on different illnesses caused by a specific family of viruses.
Certain volumes in the current series are intended to complement their
counterparts in Developments in Molecular Virology, so as to update our
knowledge of human virus diseases and the practices used in their control.
I would like to express my appreciation to the editors of this book
and to all those already engaged in the preparation of volumes to appear
in the future.
Yechiel Becker
Series Editor